Back to Search
Start Over
Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemia.
- Source :
-
British Journal of Haematology . Oct2019, Vol. 187 Issue 2, pe45-e48. 4p. 1 Chart, 1 Graph. - Publication Year :
- 2019
-
Abstract
- We conducted a retrospective analysis of AML patients treated with the combination of VEN/HMA at our institution between June 2016 and April 2019. Furthermore, we also show a promising CR/CRi rate (38%) in patients with r/r I TP53 i m AML, which includes some patients relapsing after prior alloHCT. Most patients in our cohort received decitabine as their HMA, and this preference may have been influenced by results of a study utilising 10-day courses of decitabine in I TP53 i m myeloid neoplasms and yielding a 100% response rate (Welch I et al i , [10]). Although our preliminary results with VEN/HMA appear favourable compared to the dismal outcomes reported in I TP53 i m AML patients when treated with conventional combination chemotherapy (Grossmann I et al i , [5]; Rucker I et al i , [7]), the median LFS was relatively short, and relapses occurred frequently. [Extracted from the article]
- Subjects :
- *LEUKEMIA
*ACUTE myeloid leukemia
Subjects
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 187
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 139053453
- Full Text :
- https://doi.org/10.1111/bjh.16166